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Abstract
Tyler Flockton
SYNTHESIZING GALACTOSE MODIFIED POLYMERIC NANOPARTICLES FOR
BIOFILM INHIBITION OF PSEUDOMONAS AERUGINOSA
2018-2019
Lark Perez Ph.D.
Master of Science in Pharmaceutical Sciences
Treating patients with antibiotics is becoming harder with the increase in
antibiotic resistance. This is due to the widespread antibiotic use in clinical and
agricultural settings. With antibiotic resistance outpacing new drugs making it to the
market, developing new options to treat bacterial infections is and will be important. We
created sugar modified nanoparticles to inhibit the biofilm formation of Pseudomonas
aeruginosa.
P. aeruginosa is a gram-negative opportunistic pathogen that infects its host that
has a compromised immune system. This makes it one of the most significant bacterial
infection in hospitals. P. aeruginosa uses biofilms as an attack mechanism on the host.
These biofilms are regulated through quorum sensing. Lec-A is the galactose binding
lectin in P. aeruginosa which was the lectin target for this project. By knowing the
binding pocket of the Lec-A, a galactose-modified di-block co-polymer is assembled into
nanoparticles.
In order to make the nanoparticles to work better, more galactose modified sugars
are added to the co-polymer. This was done by using Lysine to attach two galactose
modified sugars to. The polymer was assembled by adding polymer to Cyanuric Chloride
(TCT) then two lysines doubled modified galactose sugars to the TCT giving a tetra modified polymer which will then be assembled to a nanoparticle.
v
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Chapter 1
Inhibition of Pseudomonas aeruginosa Biofilm Formation with Surfaced Modified
Polymeric Nanoparticles
1. Introduction
The ongoing increase of antibiotic resistance represents a significant challenge to
modern medicine [1–3]. Due to the widespread use of antibiotics in clinical and
agricultural settings and the limited number of novel antibiotics being advanced into the
market, the development of new treatment options for bacterial infection is of paramount
importance.
Pseudomonas aeruginosa represents one of the most significant gram-negative
opportunistic pathogens involved in hospital-acquired infections. A report from the CDCNNIS (National Nosocomial Infections Surveillance, US Dept. of Health and Human
Services) identifies P. aeruginosa as the second leading cause of pneumonia, the third
leading cause of urinary tract infection, and the eighth most frequently isolated pathogen
from the bloodstream [1–7]. Further, P. aeruginosa often causes lethal infections in
cystic fibrosis and immunocompromised patients, for whom the formation of bacterial
biofilms plays a central role in infection and resistance [8,9]. Given the rapidly increasing
incidence of P. aeruginosa in the clinic coupled with the high levels of antibiotic
resistance and production of copious biofilms often found with this pathogen, the
development of novel treatment strategies is imperative [10–12].
In P. aeruginosa, biofilm formation is regulated by a cell-cell communication
mechanism known as quorum sensing, which is mediated by bacterial cell-surface lectins
involved in cellular adhesion [13,14]. Specifically, the galactose-binding lectin LecA
1

(PA-IL) and the fucose-binding lectin LecB (PA-IIL) have prominent roles in bacterial
virulence, cellular adhesion, tissue colonization, and/or invasion and biofilm formation
[15–17]. Several recent reports have evaluated approaches to inhibit the virulence and/or
biofilm formation in P. aeruginosa through inhibition of quorum sensing or lectin
binding. Notable about these anti-virulence approaches is the potential they possess for
species-selectivity by targeting the inhibition of cellular processes in a manner that
uniquely inhibits the virulence and/or infectivity of P. aeruginosa. Accordingly,
treatments developed for these P. aeruginosa-specific targets are anticipated to have a
lower impact on the beneficial commensal bacterial population and may possibly exhibit
reduced pressure for the development of antibiotic resistance.
Prior studies developing inhibitors of P. aeruginosa LecA have described monovalent and multi-valent inhibitors of this lectin and have characterized the positive effect
on inhibitor avidity through multivalency [12,17]. We rationalized that we might achieve
similar high binding avidity for LecA using a polymeric nanoparticle with multiple
copies of a LecA ligand on the surface of the particle. Further, we recognized that unlike
dendrimeric or small molecule inhibitors of LecA, the surface-modified polymeric
nanoparticles that we aimed to prepare would be capable of encapsulating a fluorescent
or drug molecule within their lipophilic core, potentially enabling future applications in
targeted antibiotic drug delivery or fluorescent labeling for diagnostic applications. Here
we report our findings on the development and anti-biofilm properties of a series of
LecA-targeted polymeric nanoparticles.
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2. Results
2.1 Synthesis of galactose-modified di-block do-polymer. The D-galactosemodified di-block co-polymer required for nanoparticle assembly (5) was prepared from
β-D-galactose pentaacetate in six steps (Scheme 1). In short, β-D-galactose pentaacetate
(1) was coupled to benzyl 4-hydroxybenzoate (2) to provide ester 3. Removal of the
benzyl protecting group by hydrogenolysis provided carboxylic acid 4, which was
coupled to 6.6 kD amine terminated di-block co-polymer [18]. Removal of the acetate
protecting groups on the sugar preceded purification of the sugar-modified polymer 1 by
dialysis using a 5 kD molecular weight cutoff (MWCO) membrane. The resulting
dialyzed D-galactose-modified polymer (5) was concentrated by lyophilization and the
resulting white powder was characterized by NMR, IR, and MALDI-MS. Having
prepared the requisite galactose-modified di-block copolymer 5, we proceeded with the
assembly of polymeric nanoparticles.

Scheme 1. Synthesis of modified di-block co-polymer for nanoparticle assembly.
Abbreviations: DCM, dichloromethane; CAN, acetonitrile; MWCO, molecular weight
cutoff
3

2.2

Nanoparticle

preparation.

Nanoparticles

were

prepared

by

flash

nanoprecipitation using established methods [18,19] with varying ratios of the modified
D-galactose polymer and unmodified di-block co-polymer to provide 100%-, 50%-, and
25%-surface-modified nanoparticles using the parameters described in Table 1. All
nanoparticles were prepared using racemic -tocopherol (vitamin E) as an inert core
stabilizer.

Table 1.
Summary of polymeric nanoparticle (NP) prepared with varying levels of surface
modification
Active Stabilizer
Formulati
on

Block copolymer

Stabilizer

Inert Core

NP Properties

Conc.
Block
Conc.
(mg/m
co(mg/m
L)
polymer
L)

Fill
er

Conc.
(mg/m
L)

Zdiamete
r (nm)1

PDI2

0%

PS-bPEG-Gal

0.00

PS-bPEG

0.40

Vit
E

0.40

88.83±4.
64

0.03
27

25% GalNP

PS-bPEG-Gal

0.10

PS-bPEG

0.30

Vit
E

0.40

73.78±2.
23

0.01
32

50% GalNP

PS-bPEG-Gal

0.20

PS-bPEG

0.20

Vit
E

0.40

74.74±2.
26

0.00
83

100%
Gal-NP

PS-bPEG-Gal

0.40

PS-bPEG

0.00

Vit
E

0.40

81.47±1
2.75

0.26
93

Data represent the mean with error described as the standard error of means of at least three independent
preparations of the particles, each with three instrumental replicates. 2 Polydispersity Index (PDI) =
(standard deviation/mean diameter) ^2. Abbreviations: VitE, vitamin E (-tocopherol).
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All D-galactose nanoparticle (Gal-NP) suspensions were prepared as 0.02 mg/mL
solutions in water and characterized in terms of particle diameters (Figure 1) and
polydispersity indexes (PDI). The particles prepared are described in this manuscript
based on the relative concentration of surface-modified D-galactose to enable direct
comparison of the effect of the prepared nanoparticles on lectin binding and biofilm
inhibition to free D-galactose, used as a control. Having prepared a series of galactosemodified polymeric nanoparticles, we conducted an evaluation of the lectin binding
properties of the prepared particles.

Figure 1. Schematic showing assembly of D-galactose surface-modified polymeric
nanoparticles. B. Particle size distribution of prepared polymeric nanoparticles. Each data
point represents the average particle diameter of an independent formulation. C.
Histogram of particle size distribution for all nanoparticles prepared in this study.

2.3 Inhibition of LecA-mediated hemagglutination. The binding affinity of the
modified nanoparticles for the P. aeruginosa lectin LecA was evaluated using a
hemagglutination assay [20]. Briefly, this assay measures the inhibition of LecA-induced
hemagglutination of rabbit erythrocytes by comparison with D-galactose as a control. The
5

exceptional effect of ligand multivalency was noted with the 100%- and 50%-modified
NP samples, which were evaluated based on the concentration of galactose on the surface
of the nanoparticles (Table 2). The strongest effect was observed with the 50%-modified
Gal-NP, showing a 992-fold increase in relative potency compared with free galactose.
The 100%-modified Gal-NP samples inhibited hemagglutination when modified with
concentrations above 6.31μM of galactose, representing a 495-fold increase in potency
relative to free galactose. The 25%-modified NP showed no inhibition of
hemagglutination up to the highest surface concentration of D-galactose evaluated (2.36
μM). A control 100%-mannose-modified polymeric NP (37.9 μM mannose) showed no
inhibition of hemagglutination, supporting the hypothesis that the inhibition of LecA is
mediated by specific interactions between the lectin and the nanoparticle surface only
with galactose modification.

6

Table 2.
Inhibition of P. aeruginosa LecA-induced hemagglutination.
Entry

Formulation

1

D-galactose
100%-Modified Dgalactose-NP
50%-Modified Dgalactose-NP
25%-Modified Dgalactose-NP
100%-Modified
mannose-NP

2
3
4
5

Hemagglutination Assay MIC
(uM)1
3125.0

Relative
Potency4
1.0

6.31

495.2

3.15

992.1

none2

-

none3

-

MIC = minimal inhibitory concentration for the hemagglutination assay following two-fold serial
dilutions of tested compounds; the MIC corresponds to the highest dilution resulting in the
inhibition of LecA-induced hemagglutination based on the relative sugar concentration. 2 No
inhibition of hemagglutination up to highest concentration evaluated (galactose concentration of
2.36μM). 3 No inhibition of hemagglutination up to highest concentration evaluated (maltose
concentration of 37.9μM). 4 Relative potency based on concentration of galactose = (MIC(Dgalactose)/MIC(ligand)).

The high potency of the particles in this assay is consistent with previous reports of
high avidity LecA binding using galactose modified dendrimers [12,20]. It is noted that
the % modification of the particle leads to maximal inhibition with the 50%-sugarmodified particles. Particles with lower galactose modification (25%-modified) showed
no inhibition of hemagglutination at the highest concentrations tested ([galactose] = 2.36
μM) and those with higher modification (100%-modified) had a two-fold higher MIC. It
is possible that a sugar concentration greater than 2.36 μM on the nanoparticles is
required for high avidity; however, higher sugar concentrations as would be present in the
100%-modified nanoparticles result in the steric inhibition of lectin binding.

7

2.4 Inhibition of P. aeruginosa PAO1 biofilm formation. Having identified that
our 100%- and 50%-D-galactose-modified polymeric nanoparticles are effective at
inhibiting LecA-induced hemagglutination, we evaluated their effect on bacterial biofilm
formation using the well-established crystal violet assay [21,22]. Briefly, P. aeruginosa
strain PAO1 was inoculated in 96-well plates in the presence of varying concentrations of
Gal-NP, controls, and/or free D-galactose. Biofilm formation was evaluated after 24 h by
removing non-adherent bacteria, crystal violet staining of the adherent cells, and
determination of absorbance at 550nm. In this assay, we observed a potent dosedependent inhibition of biofilm formation with our surface-modified Gal-NP samples
(Figure 2). Inhibition of biofilm formation was noted at D-galactose concentrations above
12.6 μM in the 100%-surface-modified nanoparticle samples and at concentrations above
6.3 μM in the 50%-surface-modified series. Again, the significance of ligand valency is
evident, as free D-galactose, even at 32,000 μM, showed no inhibition of biofilm
formation in this assay.
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1.0

Blank

32000 uM Free Gal

2.1 uM 50%GalNP

6.3 uM 50%GalNP

18.9 uM 50%GalNP

1.4 uM 100%GalNP

4.2 uM 100%GalNP

0.0

12.6 uM 100%GalNP

0.5

37.9 uM 100%GalNP

Biofilm Formation(A550)

1.5

Figure 2. Inhibition of P. aeruginosa PAO1 biofilm formation based on the crystal violet
assay. Surface-modified Gal-NP samples are described based on the % surface
modification and the relative concentration of D-galactose on the nanoparticle surface.
All data points are described as the mean of triplicate measurements with error bars
representing the standard deviation.

2.5 Evaluation of growth inhibition. To confirm that the potent biofilm inhibitory
activity observed was not due to growth inhibition by the nanoparticle samples evaluated,
we collected full growth curve data for PAO1 by monitoring OD600 (Figure 3). We were
surprised to find that the highest concentration of 100%- and 50%-modified nanoparticles
(correlating to D-galactose concentrations of 75.8 μM and 37.8 μM, respectively) did
potently inhibit bacterial growth. Despite this, no significant inhibition of growth was
noted at any of the nanoparticle concentrations evaluated in our biofilm inhibition assay.
The absence of growth inhibition supports the hypothesis that that nanoparticle-LecA
9

binding interactions inhibit bacterial biofilm formation via an antivirulence (nonantibiotic) mechanism.

Figure 3. Evaluation of P. aeruginosa PAO1 growth by monitoring OD600 with 100%-Dgalactose-surface-modified nanoparticles (A) and 50%-D-galactose-surface-modified
nanoparticles (B). No significant growth inhibition is observed with 100%-modified GalNP at concentrations below 37.9 μM or with 50%-modified Gal-NP at concentrations
below 18.9 μM. Growth inhibition was noted at concentrations two-fold higher than those
employed in the biofilm inhibition assays (100% Gal-NP at 75.8 μM and 50% Gal-NP at
37.8 μM). Error bars represent standard deviation of triplicate analysis.
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2.6 Evaluation of biofilm inhibition and morphology. We subsequently evaluated
the inhibition of biofilm formation in the hyper-virulent isolate of P. aeruginosa PA14 by
fluorescent confocal microscopy. Briefly, 24-h biofilms were prepared by inoculation of
PA14-GFP [23] into Luria broth (LB) containing the appropriate treatments or controls.
The resulting biofilm was then evaluated by fluorescent confocal microscopy. In this
experiment, we observed clear changes in the overall biomass and average biofilm
thickness of the Gal-NP-treated samples, consistent with our observations in the crystal
violet assay. Additionally, in this experiment, we captured distinct changes in the
morphology of the biofilm that are evident at sub-inhibitory concentrations. These
observations further support the inhibition of cellular adhesion by D-galactose surface
modified nanoparticles.
Within the 100%- and 50%-surface-modified samples of nanoparticles we observed
the inhibition of biofilm formation based on evaluation of biofilm biomass and average
biofilm thickness at concentrations above ~19.5 μM; however, effects on biofilm
morphology were apparent at even lower concentrations (Figure 4). The slightly higher
concentrations required to inhibit biofilm formation in the hypervirulent PA14 strain,
compared with our crystal violet assay with PAO1, are consistent with previous studies of
this bacteria [24,25]. In this assay, we observed no inhibition of biofilm formation by free
D-galactose, even at concentrations of 48,000 μM (Figures 4 and 5). Visual inspection of
the images collected (Figure 4 and Supporting Information) show that with increasing
concentration of D-galactose-modified nanoparticles the biofilm begins to display
increasing numbers of spaces within the biofilm structure (Figure 4, panel A vs. B vs. D).
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This effect is consistent with the anticipated inhibition of cellular adhesion achieved by
inhibiting the activity of LecA in the presence of Gal-modified nanoparticles.

Figure 4. Fluorescent confocal microscopy evaluation of P. aeruginosa PA-14 biofilms.
Samples treated with Gal-NP show inhibition of biofilm formation. The biofilm
morphology at sub-inhibitory concentrations of Gal-NP (e.g. 100%-modified at 9.75 μM)
shows evidence of anti-adhesive properties of Gal-NP, which increase with higher
concentrations. For additional images see Supporting Information.

Quantification of the biomass and average biofilm thickness of the confocal images
using the program Comstat2 shows dose-dependent inhibition of biofilm formation
(Figures 5A and B). Most striking is the quantification of biofilm surface area as a
function of volume. This calculation nominally provides a measure of the quantity/size of
spaces within the biofilm structure. Consistent with the hypothesis that Gal-NP inhibit
cellular adhesion without inhibiting growth/viability, we observe a dose-dependent
increase in the biofilm surface area/volume (Figure 5C).
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Figure 5. Quantification of (a) biofilm total biomass, (b) average biofilm thickness, and
(c) biofilm surface area/volume from fluorescent confocal microscopy analysis. Images
were analyzed using Comstat2 processing of duplicate analysis and are reported as means
with error bars representing standard deviations.

3. Discussion
Recently, significant interest has been directed at the development of antivirulence
strategies to combat infectious diseases. As these approaches do not directly impact
viability or growth, a reduced selective pressure for resistance is anticipated. For the
inhibition of biofilm formation, many antivirulence agents being developed focus on the
inhibition of the quorum-sensing signaling pathways [14,24,26] or inhibition of bacterial
adhesion [20,27,28]. Bacterial lectins are implicated in key roles in bacterial adhesion
and biofilm formation, including the lectins LecA and LecB, which play a prominent role
in P. aeruginosa. Here we report the development of the first LecA-targeted surfacemodified polymeric nanoparticle. The particles prepared showed high avidity for LecA in
the inhibition of hemagglutination, consistent with a beneficial effect of multivalent
display of the lectin ligand on the particle surface. We observed greater than 100-fold
enhancement in potency, compared with free D-galactose in the assay with 100%- and
50%-surface modified D-galactose nanoparticles. Further, we demonstrated potent
13

inhibition of P. aeruginosa biofilm formation in the presence of these surface-modified
nanoparticles, demonstrating the anti-virulence potential of these novel inhibitors of the
P. aeruginosa lectin LecA.
Previous studies have shown that LecA is cytotoxic [29] and has an important role in
cellular adhesion and lung infection [17]. LecA is a homotetramer and displays
specificity for galactose. Due to the high affinity of LecA for galactose, numerous
multivalent and dendrimer structures have been developed as inhibitors of this protein
[12,20,27,28]. The significant increase in LecA binding potency noted in these
dendrimeric constructs was captured in the polymeric nanoparticles in this study, which
were found to be potent inhibitors of LecA-induced hemagglutination and bacterial
biofilm formation.
Notably, the assembly of nanoparticles as highly multivalent scaffolds for lectin
binding avoids many of the synthetic challenges of dendrimer synthesis [30,31].
Accordingly, we anticipate that the application of polymeric nanoparticles to achieve the
high lectin-binding potency observed with dendrimers, as demonstrated here, will serve
as a powerful and useful complimentary approach for the inhibition of bacterial lectins
and other cell-surface receptors. Self-assembly of sugar-modified di-block co-polymers
using flash nanoprecipitation [19] further enables ready introduction of multiple different
ligands to enable targeting multiple biological targets with a single nanoparticle
construct, further enhancing biological activity.
Polymeric nanoparticles have been extensively studied in several medical
technologies, especially in the area of drug delivery [11,32–37]. The advantages of
improved pharmacokinetics and therapeutic properties, including mucus penetration [38],
14

continue to stimulate interest in the field. As demonstrated here, surface modification of
the nanoparticle enables targeting of the constructs to the bacterial pathogens of interest,
potentially enabling species-specific delivery of drugs, diagnostic reagents, or other small
molecules.
4. Conclusion
In conclusion, polymeric nanoparticles synthetically modified to provide surface
display of conjugated D-galactose bind to the P. aeruginosa lectin LecA with high
potency. The benefit of high ligand valency to achieve high avidity lectin binding is
efficiently realized in these constructs. Several of the polymeric nanoparticles were found
to inhibit biofilm formation in a manner consistent with an antivirulence (anti-adhesion)
mechanism of action, providing a new and powerful technology for species-specific
inhibition of bacterial virulence.

15

Chapter 2
Synthesis of Tetra-Galactose Modified Polymers
The data that was acquired from the mono Galactose modified nanoparticles was
very promising. As the active functionality contributing to the observed inhibition of P.
aeruginosa biofilms is only a simple, polymer linked, naturally occurring sugar the
observation of inhibition to the levels we observed is especially notable. In our studies we
observed activity at relative concentrations of 38µM of Galactose on the nanoparticle
surface contrasting observing no activity up to 38,000µM of free Galactose. Therefore,
while the simple Galactose sugar is necessary for activity, it is not sufficient. In addition
to the presence of Galactose it is critical that the sugar be localized onto the particle
surface. Importantly, unmodified nanoparticles and Mannose modified particles show no
inhibition of P. aeruginosa biofilm. The mono Galactose modified nanoparticles have a
significant effect on the biofilm inhibition of P. aeruginosa. This was a great first step to
making bacteria selective antibiotics.
The next step of this project is to make new and improved Galactose modified
nanoparticles; however, the new nanoparticles will have more modified Galactose going
from mono Galactose to multi-valent Galactose. The first target molecule was to make a
di-valent Galactose molecule to essentially double the amount of sugars on the
nanoparticles. While making this molecule, we figured out that we could quadruple the
amount of sugars on the nanoparticles. This can be accomplished by using Cyanuric
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Chloride and modifying it with one of the chlorines substituted with the polymer and the
other two chlorines substituted with the di-valent galactose sugars that were made.
5. Results
5.1 Optimization of Mono-Boc diamine linker. The first step to making the tetra
galactose modified polymer was to synthesize the mono-boc diamine linker that will be
linked to lysine. A simple boc protecting mechanism turned out to be more challenging to
selectively add one boc protecting group to a diamine substrate. First attempt was to do a
1:1 stoichiometry which should give mono-boc to the diamine. After looking at the HNMR, the product ended up being bis-boc on the diamine which is not what was the goal.
The reaction conditions were screened in order to optimize the reaction scheme to create
the mono-boc diamine linker. Table 3 shows the reaction conditions that were screened.
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Table 3.
Screened reaction conditions for the optimization of mono-boc diamine linker
Stoichiometry
(Diamine : Boc)

Temperature

Solvent

Mono-boc

Yield

1:1

23˚C

DCM

No

0%

1:1

0˚C

DCM

No

0%

1:1

-40 ˚C

DCM

No

0%

1:1

-80 ˚C

DCM

No

0%

1:1

23˚C

Methanol

No

0%

1:1

23˚C

Ethyl Acetate

No

0%

1:0.9

23˚C

DCM

Yes

< 2%

1:0.75

23˚C

DCM

Yes

15%

1:0.4

23˚C

DCM

Yes

95%

1:0.1

23˚C

DCM

Yes

90%

1.0 eq 6
0.4 eq

95% YIELD

7

Scheme 2. Optimized mechanism of mono-boc protected diamine linker for galactose
modified lysine.
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The conformation of the product was done by analyzing the H-NMRs of the
products. In figure 6 the left H-NMR is the bis-boc diamine confirmed by the
integration of the boc protons at δ1.48 showing 18. The reaction conditions for that
was a 1:1 ratio of diamine and boc. After screening the reaction conditions,
ultimately the best conditions were decreasing the amount of boc used to 0.4 eq.
After doing this change, the H-NMR confirmed that the reaction did indeed give
mono-boc instead of bis-boc on the diamine. After purification the H-NMR shows
the integration of 9 protons at δ1.46.

Figure 6. H-NMR comparison of bis-boc (Left) and H-NMR of mono-boc (7) (Right).
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Scheme 3. Synthesis of TCT coupled to Diethylene Glycol Monomethyl Ether.

5.2 Confirmation of di-chlorotriazine PS-PEG. In order to test that the PSPEG-OH 6.6kD was binding to TCT, we used Diethylene Glycol Monomethyl Ether as a
template to see binding. Diethylene Glycol Monomethyl Ether is a much smaller PEG
which allows us to interpret if we are getting modified TCT or not. In order to test this,
knowing the what the starting material H-NMR and C-NMR was crucial. Diethylene
Glycol Monomethyl Ether’s H-NMR shifts are important because we wanted to see if it
was binding to the TCT. Looking at the shift in starting material H-NMR and product HNMR it is clear that the Diethylene Glycol Monomethyl Ether bound to something. As
shown in Figure 7, the protons shifted higher following ChemDraw predictions.
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Figure 7. H-NMR of unreacted Diethylene Glycol Monomethyl Ether (Left), reacted
Diethylene Glycol Monomethyl Ether with TCT (Right)

The next thing to check is if the Diethylene Glycol Monomethyl Ether is bound to TCT.
In order to characterize this, C-NMR of the starting material of TCT and C-NMR of
product are interpreted. The starting material TCT’s C-NMR shows one peak at δ172
which are for the 3 carbons in TCT. When the C-NMR of product is looked at, there is 1
new peak that shows up at δ171. The new peak is lower and shorter telling us that
Diethylene Glycol Monomethyl Ether was bound once to TCT.
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Figure 8. C-NMR comparison of unreacted TCT (Left) and Diethylene Glycol
Monomethyl Ether reacted with TCT (Right)

Scheme 4. Mechanism of addition of PS-PEG-OH (6.6kD) to TCT.
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Figure 9. C-NMR of TCT reacted with PS-Peg-OH (6.6kD) confirmation compared to
Scheme 3 C-NMR. Important peaks at δ172 and δ171.

5.3 Synthesis of tetra galactose-modified di-block co-polymer. In order to
make the final product, the bis galactose lysine with the diamine linker needed to be
added to the TCT at the other available sites of the TCT. After doing some research, in
order to get both of the chorlines to leave and have our lysine added, the termperature
needs to get to 80°C. The tricky part of this reaction was to get it to actually work. While
on paper it seemed trivial, the execution was much complicated. It is not entirly known
how polymers are position in solution, but increasing temperature could cause the
polymer to rotatate around itself not allowing the lysine to bind to the polymer. We need
heat to get the reacton to work so that needs to be done. The first attemped was to just stir
and heat at 80°C for 2 day using an oil bath. This did not show any modification of the
TCT with Lysine. We got it to temperature but still no reaction. The next condition we
looked at was the stiring, maybe the stir bar on the plate is not stiring enough. We then
used the sonicator at 80°C. This again did not change the outcome and there was still no
modification of the TCT. The last attempt was two things that were changed. The first
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thing that was changed was the equivilence of the lysine. Instead of doing just 2
equivilence of lysine, this was increased to 10 equivilence. The second change was to use
the microwave. Thinking that the microwave will heat it from all around the reacting vs
from the outside in like tradition oil baths. The microwave also decreases the time of the
reaction turning a 2 day reaction into 2 hours. The reaction also only needed to be heated
to 70°C with 100 power. This change in the reaction gave up product which was
confirmed by MALDI show in Figure 10.

Figure 10. Maldi mass of product 13 in green and the starting material PS-PEG-OH (7.6
kD) in pink.
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Instead of targeting a sugar with a carboxylic acid to couple to an amine-terminated
polymer as before, a strategy that would employ a sugar with a free amine to couple to an
electrophilic polymer reagent (Figure 3). In three steps from bis-Fmoc-Lys-OH (8), I can
prepare multi-gram quantities of intermediate 9. I envisioned coupling this intermediate,
after liberation of the Boc-protected benzyl amine, to an electrophilic polymer species.
My current approach involves using cyanuric chloride (TCT) which is a chlorinated
derivative of 1,3,5-triazine that has been linked the polystyrene peg to one chlorine
position (12). If the remaining two electrophilic sites on the heteroaromatic linker can be
engaged in reaction with the sugar-containing amine then two lysines that are double
modified with galactose would be incorporated to enable the assembly of a tetra-modified
galactose polymer. This can be done by doing the boc deprotection of the lysine with the
di-galactoce modified sugars (10) and reacting this with (12) in the microwave for 2
hours at 70°C with 100 power. Product (13) was confirmed by MALDI.
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Chapter 3
Supporting Information
6. Materials and Methods
6.1 General experimental. Unless otherwise noted, all reactions were performed in
flame-dried glassware under an atmosphere of nitrogen or argon using dried reagents and
solvents. All chemicals were purchased from commercial vendors and used without
further purification. Anhydrous solvents were purchased from commercial vendors.
Flash chromatography was performed using standard grade silica gel 60 230-400
mesh from SORBENT Technologies or using a Biotage Flash Purification system
equipped with Biotage SNAP columns. All purifications were performed using gradients
of mixtures of ethyl acetate and hexanes. Analytical thin-layer chromatography was
carried out using Silica G TLC plates, 200 μm with UV254 fluorescent indicator
(SORBENT Technologies), and visualization was performed by staining and/or
absorbance of UV light.
NMR spectra for small molecules were recorded using a Varian Mercury Plus
spectrometer (400 MHz for 1H-NMR; 101 MHz for

13

C-NMR). Chemical shifts are

reported in parts per million (ppm) and were calibrated according to residual protonated
solvent. Mass spectroscopy data was collected using an Agilent 1100-Series LC/MSD
Trap LC-MS or a Micromass Quattromicro with a Waters 2795 Separations Module LCMS with acetonitrile containing 0.1% formic acid as the mobile phase in positive
ionization mode. Small molecule purity was determined on an Agilent 1100 series
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equipped with a Phenomenex Kinetex 2.6 µm C18-UPLC column using a gradient of
water to acetonitrile with 0.1% TFA.
All final compounds were evaluated to be of greater than 90% purity by analysis of
1

H-NMR, 13C-NMR, and/or analytical HPLC.
6.2 Synthesis of D-galactose-modified polymers. (2S,3R,4S,5S,6R)-6-

(acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate, 2. D-galactose
(5.00 g, 27.75 mmol) was dissolved in acetic acid (185 mL, 0.15 M) at room temperature.
Acetyl bromide (16.40 mL, 222.02 mml) was added and the mixture was allowed to stir
for 1 hour. The resulting solution was washed with toluene (2x, 40 mL), dried over
sodium sulfate, and concentrated to dryness. The residue was purified by flash
chromatography using a gradient of hexanes to EtOAc to provide (2S,3R,4S,5S,6R)-6(acetoxymethyl) tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate. Characterization data
was consistent with a commercial sample of this compound.
(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4((benzyloxy)carbonyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triyl

triacetate,

4.

(2S,3R,4S,5S,6R)-6-(acetoxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetrayl tetraacetate, 2 (2
g, 5.12 mmol) was dissolved in dichloromethane (10 mL, 0.5 M) at room temperature.
Hydrobromic acid (33% in AcOH, 1.485 mL) and acetic acid (3.015 mL, 1.14 M) were
added and the mixture was allowed to stir. After 30 minutes, the solution was diluted
with 50 mL of DCM, washed with sodium bicarbonate, dried with sodium sulfate, and
concentrated to dryness. The residue (2 g) was re-dissolved in DCM (30 mL, 1.5 M) and
treated with benzyl-4-hydroxybenzoate, 3 (2.34 g, 10.03 mmol), tetrabutylammonium
hydrogensulfate (1.74 mg, 5.12 mmol), and 0.5 M sodium hydroxide (10 mL, 0.5 M).
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The biphasic mixture was allowed to stir overnight at room temperature, was diluted with
DCM and acidified with 1M HCl, extracted with DCM (3 x 50mL), dried over Na2SO4,
and concentrated to dryness. The residue was purified by flash chromatography using a
gradient of hexanes to EtOAc to provide (2R,3S,4S,5R,6S)-2- (acetoxymethyl)-6-(4((benzyloxy)carbonyl)phenoxy) tetrahydro-2H-pyran-3,4,5-triyl triacetate, 4 (1.006 g,
1.848 mmol, 40.76%). 1H NMR (400 MHz, CDCl3) δ1H NMR (400 MHz, CDCl3) δ 7.96
(d, J = 8.9 Hz, 2H), 7.40–7.22 (m, 5H), 6.95 (d, J = 8.4 Hz, 2H), 5.48–5.37 (m, 2H), 5.27
(s, 2H), 5.11–5.01 (m, 2H), 4.20–3.95 (m, 3H), 2.11 (s, 3H), 1.98 (s, 6H), 1.94 (s, 3H).
13

C NMR (101 MHz, CDCl3) δ 170.44, 170.30, 170.19, 169.44, 165.88, 160.46, 136.19,

131.84, 128.72, 128.37, 128.25, 125.14, 116.30, 98.93, 71.39, 70.84, 68.59, 66.93, 66.76,
66.76, 61.50, 20.82, 20.79, 20.76, 20.69, 0.12. ESI-MS: predicted for C28H31O12 [M+H]+
559.544, observed, 559.569.
4-(((2S,3R,4S,5S,6R)-3,4,5-triacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2yl)oxy)benzoic

acid,

5.

(2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-

((benzyloxy)carbonyl)phenoxy)tetrahydro-2H- pyran-3,4,5-triyl triacetate, 4 (0.719 g,
1.320 mmol) was dissolved in methanol (6.6 mL, 0.2 M) and palladium on carbon (10%,
16 mg, 0.1 mmol) was added to the reaction flask at room temperature. Hydrogen was
added via balloon and the reaction was stirred overnight at room temperature. The residue
was separated by vacuum filtration washing with methanol to yield 4-(((2S,3R,4S,5S,6R)2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)

methoxy)benzoic

acid, 5 (571.2 mg, 1.219 mmol, 61.85%). 1H NMR (400 MHz, CDCl3) δ 8.05 (d, J = 8.3
Hz, 2H), 7.03 (d, J = 8.3 Hz, 2H), 5.57–5.43 (m, 2H), 5.20–5.07 (d, J = 51.1 Hz, 2H),
4.28–4.06 (d, J = 84.7 Hz, 3H), 2.19 (s, 3H), 2.06 (s, 6H), 2.02 (s, 3H).
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13

C NMR (101

MHz, CDCl3) δ 171.98, 171.91, 171.38, 171.22, 161.55, 132.97, 132.72, 117.02, 115.98,
99.36, 72.27, 72.16, 70.02, 68.67, 62.60, 49.00, 24.74, 20.69, 20.60, 20.54, 20.50, 20.49,
13.93. ESI-MS: predicted for C21H24O12Na [M+Na]+ 491.401, observed, 491.477.
PS-b-PEG-Galactose, 1. To a room temperature solution of 4-(((2S,3R,4S,5S,6R)2,3,4,5-tetrahydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)

methoxy)benzoic

acid, 5 (20.5 mg, 0.068 mmol) in DMF (340uL) was added (Benzotriazol-1yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (30.1 mg, 0.068 mmol) and
the mixture was allowed to stir for 5 minutes before the addition of PS-b-PEG-NH2 (150
mg, 0.023 mmol, 6.6 kD, prepared from PS-b-PEG-OH as previously described [18]).
The resulting solution was stirred at room temperature overnight. The reaction was
quenched by the addition of water (1 mL) and EtOH (1 mL), and loaded into a 3.5 kD
MWCO dialysis cassette (PierceTM Slide-A-LyzerTM G2, Thermo Scientific). The mixture
was dialyzed into water for 12 h, at which time the dialysis cassette was transferred to a
fresh solution of water and further dialyzed for an additional 12 h. After dialysis, the
retained solution was lyopholyzed to provide PS-b-PEG-galactose, 1, as a white powder
(153.6 mg, quantitative). The product was characterized by MALDI-MS (Bruker
MicroFlex LFR MALDI-TOF) in positive linear detection mode using a matrix of
dithranol:polymer of 1:1 evaporated from DCM onto a polished steel target. Collected
spectra were analyzed with the Flex Analysis software (Bruker); the unmodified PS-bPEG-NH2 was evaluated in the same manner as a standard. The observed m/z for PS-bPEG-NH2 was 6212.07, and the observed m/z for PS-b-PEG-galactose was 6501.40,
consistent with complete polymer modification (anticipated Δ m/z for polymer
modification = 282.24).
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6.3 Nanoparticle assembly. Nanoparticles with defined levels of surface
modification were prepared through flash nanoprecipitation (FNP) as previously
described [18,19,39]. Briefly, PS, vitamin E (VitE), PS-b-PEG, PS-b-PEG-galactose,
and/or PS-b-PEG-mannose were dissolved at defined compositions in THF and rapidly
micromixed with an equivalent volume of water within a confined impingement jet
mixer, manufactured using HDPE (The Inventors Shop, Cinnaminson, NJ, USA),
following the specifications provided [40], and diluted tenfold in a water collection bath.
Particles with 0–100%-surface-modification of galactose or mannose were prepared
using defined combinations of PS-b-PEG/PS-b-PEG-galactose or PS-b-PEG-mannose.
Vitamin E was used as the core bulking material in all NP formulations. Particle sizes
were assessed with dynamic light scattering analysis (90Plus Particle Size Analyzer,
Brookhaven Instruments Corporation). Size distributions were determined with
backscattering measurements from 658-nm illumination and displayed as intensityweighted distributions; ‘particle diameter’ is the hydrodynamic diameter as calculated by
DLS based on the Stokes Einstein equation using instrumental software. The composition
of particles formed and particle size characterization data is provided in Table 1.
6.4 Hemagglutination assay. The LecA-induced hemagglutination assay was
performed as reported with modifications [20]. LecA (PA-IL) was purchased from
Sigma-Aldrich and used as received. Rabbit red blood cells (Innovative Research) at
100% were washed three times with 150 mM NaCl solution then diluted to 5% with NaCl
(150 nM) solution. A hemocytometer was used to count the number of red blood cells
that were in red blood cell solution and solutions were normalized to 2.94 x 1014
cells/mL. To find the minimal full hemagglutination inhibition concentration for LecA, a
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serial dilution was performed from a stock solution of 1 mg/ml LecA. Briefly, LecA (15
µl) was diluted into Tris buffer (Tris 20 µM, NaCl 100 mM, CaCl2 100 µM, pH = 7.5, 35
µl) in 96-well microtiter V-bottom plates and was subjected to a two-fold serial dilution.
Normalized 5% blood solution (10µl) was added to each well and incubated for 30
minutes at room temperature. After incubation, the plate was centrifuged for 1 minute at
low rpm. The minimum full hemagglutination inhibition for LecA was found to be 1.2
µg/ml. Further analysis of inhibition of LecA-induced hemagglutination was performed
with LecA at 4xHU (4.8 µg/ml). Briefly, 25 µl of each nanoparticle formulation was
subjected to a two-fold serial dilution in Tris buffer and LecA was added to a final
concentration of 4xHU. The plate was then incubated for 2 hours at room temperature.
After incubation, normalized 5% blood solution (10 µl) was added. The plate was then
incubated for 30 minutes at room temperature and then centrifuged for 1 minute at low
rpm before analysis.
6.5 Crystal violet biofilm inhibition assay. The effect of inhibitors on static biofilm
formation was evaluated using the crystal violet staining method with P. aeruginosa
strain PAO1 [25] following the established procedure [41]. Briefly, overnight cultures of
P. aeruginosa PAO1 were diluted 1:100 into fresh LB media. Compounds were added at
the indicated concentrations in a 96-well microplate before static incubation at 37 C for
24 hours. After incubation, the plates were thoroughly rinsed to remove planktonic cells
and the adherent cells were quantified by staining with crystal violet and measurement of
A550. The assay was performed with five replicates for each compound concentration.
After exclusion of the highest and lowest absorbance readings the remaining triplicate
readings were described as means with error bars representing standard deviations.
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6.6 Growth inhibition assay. The effect of nanoparticles on bacterial growth was
evaluated with P. aeruginosa strain PAO1 [25]. Overnight cultures of P. aeruginosa
PAO1 were diluted 1:100 into fresh LB media. Nanoparticle formulations/compounds
were added at the indicated concentrations in a 96-well microplate. The plate was placed
in a Molecular Devices SpectraMax i3x incubating plate reader set at 37 C with shaking.
Measurement of A600 was recorded every 15 minutes for the duration of the experiment.
Readings are reported as means with error bars representing the standard deviations of
triplicate analyses.
6.7 Fluorescent confocal microscopy. The effect of inhibitors on static biofilm
formation was evaluated by confocal fluorescence microscopy with P. aeruginosa strain
PA14 [25] following the established procedure [42]. Briefly, overnight cultures of PA14GFP [23] were diluted 1:100 into the designated media. Compounds were added at the
indicated concentrations in 96-well microplates with optical grade glass bottoms
(Corning) before static incubation at 37 C for 24 hours. After incubation, the samples
were imaged on a Nikon Eclipse TI confocal microscope equipped with a 10X lens.
Images were acquired from a central point in each well of the microplate. Each
compound concentration was evaluated in duplicate. Image stacks were analyzed using
Comstat2 [43, 44].
6.8. Synthesis of Tetra-Galactose Modified Polymers.
Mono-Boc Diamine 7. p-Xylyldiamine (0.200 g, 1.468 mmol) in DCM at 0°C.
Triethylamine (0.500 mL, 3.5232 mmol) was added to cold solution. Next, a separate
solution of Di-tert-butyl pyrocarbonate (0.1282 g, 0.5873 mmol) in DCM was added to
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the first solution. This reaction was stired overnight (18hrs) to room temperature (23°C).
The reaction was converted in vacuum and redissolved in DCM (30mL) washed with
bicarb, brine, dryed, concentrated. 7 (0.1318 g, 0.5577 mmol, 95%)
Bis-Fmoc Lysine Mono-Boc Linker 9. To a solution of Bis-Fmoc-L-lysine (2.499
g, 4.23 mmol) and Mono-Boc Diamine 7 in DMF, N,N-diisopropylethylamine (3.55 mL,
20.30 mmol) and (Benzotriazol-1-yloxy) tripyrrolidinophosphonium
hexafluorophosphate (2.64 g, 5.07 mmol) were added and reaction ran for 4 hours.
Reaction was crashed out with water, the white solids were filtered, the white solids were
then treated with Methanol and stirred overnight. Ten white solids were filtered out and
were kept for further use. 9 (1.8276 g, 2.259 mmol, 53.5%)
Bis-Galactose Lysine Mono-Boc Linker 10. To a solution of Bis-Fmoc Lysine
Mono-Boc Linker 9 (0.200 g, 0.2472 mmol) in DMF, 1,8-Diazabicyclo[5.4.0]undec-7ene (0.369 mL, 2.472 mmol) was added. This reaction was stirred at room temperature
(23°C) for 30 minutes. Once done, the reaction was treated with 24 mL of Diethyl Ether
and stirred for 5 minutes then placed into the freezer for 30 minutes. The supernatant was
removed and the solids were concentrated and used crude (Lysine Mono-Boc Linker)
without further purification. The crude product (0.2472 mmol) was made into a solution
with DMF and Modified D-Galactose 4 (0.2895 g, 0.6180 mmol) at room temperature
(23°C). To this solution, N,N-diisopropylethylamine (0.2153 mL, 1.236 mmol) and
(Benzotriazol-1-yloxy) tripyrrolidinophosphonium hexafluorophosphate (0.3216 g,
0.6180 mmol) were added and stirred for 4 hours at room temperature (23°C). Once
done, the reaction was quenched with water (50 mL) and vacuum filtered. The white
solids were extracted and concentrated to yield product 10 (0.292 g, 0.231 mmol, 93.4%)
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Di-Chlorotriazine PS-PEG (6.6 kD) 12. To a solution of PS-PEG-OH (6.6 kD)
(0.1037 g, 0.01364 mmol) in DCM, Trichorotriazine (0.0503 g, 0.2729 mmol) and N,Ndiisopropylethylamine (0.006 mL, 0.03411 mmol) were added. The reaction ran for 48
hours at room temperature (23°C) and mixed by sonication. Rotavaped to dryness and
crashed out product with Diethyl Ether. Solids were filtered out to produce 12 (0.0876 g,
0.01296 mmol, 95%)
Tetra-Galactose Modified Polymer 13. To a solution of 10 (0.1726 g, 0.1364
mmol) in DCM, Hydrogen chloride, 4M in 1,4-dioxane (682 µL,) was added and the
reaction was run overnight at room temperature (23°C). The reaction was concentrated
giving product Bis-Galactose Lysine linker and used crude without any further
purification. The next step was to make a solution of previous product of Bis-Galactose
Lysine linker (crude, 0.01364 mmol) and Di-Chlorotriazine PS-PEG (6.6 kD) 12
(0.08766 g, 0.01296 mmol) in DCM. To this solution, N,N-diisopropylethylamine
(0.0010 mL, 0.05456 mmol) was added to the solution. This reaction was run at 70°C for
1 hour in the Microwave to produce product 13.
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6.9 H-NMR and C-NMR of Intermediates and Product
H-NMR of intermediate 9
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H-NMR of intermediate Fmoc Deprotection of intermediate 9
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H-NMR of intermediate 10
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H-NMR of intermediate 12
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H-NMR of intermediate 13
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